Last reviewed · How we verify
Biological：JS002
At a glance
| Generic name | Biological：JS002 |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological：JS002 CI brief — competitive landscape report
- Biological：JS002 updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI